Atherectomy Devices Market Size & Share 2026-2035

Atherectomy Devices Market Size

The atherectomy devices market was valued at USD 866.4 million in 2025 and is projected to increase from USD 941 million in 2026 to USD 1.6 billion by 2035, reflecting a 6.4% CAGR. Historical market value rose from USD 660.4 million in 2022 to USD 794.6 million in 2024, a 9.7% historical CAGR.

Demand is rooted in the treatment burden created by peripheral artery disease (PAD) and coronary artery disease (CAD), particularly where calcification, chronic total occlusions, or in-stent restenosis complicate conventional balloon-based intervention. PAD affected an estimated 113 million people globally in 2019, with 10.5 million new cases annually; elevated fasting plasma glucose, systolic blood pressure, and tobacco exposure were the leading attributable risk factors. ^{[1]PMC/National Library of Medicine, Global burden of peripheral artery disease and its risk factors, 1990-2019. pmc.ncbi.nlm.nih.gov} Ischemic heart disease affected 254.3 million people globally in 2021, preserving a substantial addressable population for coronary plaque-modification procedures. ^{[2]PubMed/National Library of Medicine, Global burden of ischemic heart disease and its risk factors, 1990-2021. pubmed.ncbi.nlm.nih.gov}

Atherectomy systems mechanically modify or remove plaque through orbital, laser, directional, or rotational mechanisms. Their clinical role is not interchangeable across lesions or care settings. Device selection depends on vessel anatomy, calcium burden, lesion location, embolic-risk management, imaging capability, and the operator's experience. As endovascular treatment moves into more complex disease, plaque preparation has become more consequential to procedural strategy rather than a uniform substitute for angioplasty or stenting.

The historical growth rate exceeded the forecast CAGR, indicating that adoption is moving from an earlier expansion phase toward a more selective market shaped by evidence requirements and cost scrutiny. Growth remains durable in peripheral vascular intervention, but it will be moderated where payers and clinical guidance limit broad use or require stronger lesion-specific justification.

Key Drivers

Increase in preference for minimally invasive procedures

Endovascular intervention can reduce hemodynamic stress, facilitate moderate-sedation treatment, shorten hospital stays, and lower periprocedural complication exposure relative to surgical revascularization in appropriate patients. These characteristics matter most for patients with comorbid diabetes, renal impairment, or frailty, for whom avoiding open surgery may improve the feasibility of revascularization. Atherectomy benefits when clinicians require a catheter-based method to prepare calcified or occlusive lesions before adjunctive therapy.

The site-of-care transition reinforces this driver. In peripheral vascular intervention, atherectomy use was 5.37 times higher in ambulatory surgery centers (ASCs) and 16.79 times higher in office-based laboratories than in hospital outpatient departments after adjustment, while technical success remained at least 92% across settings. ^{[3]PubMed/National Library of Medicine, Site-of-care differences in peripheral vascular intervention outcomes. pubmed.ncbi.nlm.nih.gov} This does not establish that atherectomy is necessary in every outpatient procedure; it shows that outpatient procedural models can concentrate utilization where operators, equipment, and reimbursement support complex endovascular care.

Growing target patient population

Global PAD prevalence reached 236.62 million adults aged 25 years and older in 2015, and prevalence was higher in high-income countries than in low- and middle-income countries. More recent modeling projects a 220% increase in global PAD burden by 2050, with more than half of future cases expected in low- and middle-income countries. The disease burden expands the long-run opportunity, but also shifts the commercial challenge toward markets where affordability, diagnosis, and intervention capacity remain uneven.

Diabetes is a particularly important demand amplifier because it promotes vascular inflammation and atherosclerosis while increasing the risk of adverse cardiovascular events in people with PAD. Suppliers that can demonstrate value in complex diabetic limb disease, while supporting distal access and imaging workflows, are better positioned than those relying on broad prevalence statistics alone.

Technological advancements in atherectomy devices

Technology is improving the precision with which clinicians characterize and modify calcified lesions. Intravascular imaging-guided percutaneous coronary intervention has been associated with lower target lesion revascularization, target vessel revascularization, and major adverse cardiovascular events than angiography-guided intervention in randomized evidence. The value proposition for atherectomy is consequently shifting from plaque removal alone toward a workflow that combines lesion assessment, targeted modification, and confirmation of procedural result.

For orbital atherectomy, the ECLIPSE randomized trial found that orbital atherectomy before drug-eluting stent implantation created more calcium fractures and greater fracture depth than balloon angioplasty in severely calcified coronary lesions, although target-vessel failure at one year was similar between groups. That distinction is commercially material: better calcium modification does not automatically translate into superior short-term clinical outcomes for every patient. Device adoption will therefore depend on identifying lesion subsets in which procedural preparation changes a clinically meaningful downstream outcome.

Rising prevalence of PAD

The rise in PAD is linked to modifiable cardiometabolic risks as well as demographic aging. High glucose, hypertension, tobacco exposure, hypercholesterolemia, and diabetes are persistent drivers of symptomatic vascular disease. As these risks accumulate, providers face a larger flow of patients requiring surveillance, wound management, and possible revascularization.

In the United States, approximately 6.5 million adults aged 40 years and older have PAD, and many remain asymptomatic until disease is advanced. Delayed detection can increase lesion complexity when patients enter the treatment pathway, which supports demand for vessel-preparation tools but also raises the clinical and economic consequences of inappropriate use.

Key Restraints

High cost of devices and associated procedures

Atherectomy adds device expenditure, procedural planning, and, in some cases, imaging or embolic-protection costs to a revascularization episode. The economic case is strongest when lesion characteristics make plaque modification likely to reduce complications, bailout stenting, repeat intervention, or length of stay. Where that link is not clearly demonstrated, procurement teams and payers can favor lower-cost alternatives.

Coverage conditions make this restraint visible. Medicare's peripheral arterial disease policy covers directional, orbital, rotational, and laser atherectomy for short-to-medium calcified lesions, while also recognizing evidence limitations relative to other endovascular options. ^{[4]Centers for Medicare & Medicaid Services, LCD L40228: Peripheral arterial disease endovascular management, active. cms.gov} In the United Kingdom, NICE states that evidence for plaque-excision devices in femoropopliteal lesions is inadequate in quality and requires special governance, consent, and audit arrangements. These policies narrow the addressable procedure pool even when clinical need is high.

Steep learning curve and operator dependency

Atherectomy outcomes depend on lesion crossing, device positioning, speed or cutting strategy, embolic-risk assessment, and appropriate use of adjunctive therapy. These requirements create training costs and slow adoption outside experienced vascular and interventional cardiology centers. The constraint is particularly acute in systems expanding cath-lab capacity faster than specialist procedural expertise.

Regulatory compliance adds another layer in Europe. Under the EU Medical Device Regulation framework, cardiovascular catheters such as atherectomy devices are generally subject to Class III requirements, and transition provisions can affect legacy-device recertification. Manufacturers must therefore pair product training with quality, clinical-evidence, and post-market capabilities; a technically differentiated device without this infrastructure can face delayed or limited uptake.

Training and evidence requirements create a scale advantage for established manufacturers. Companies that can support imaging-enabled case selection, proctoring, complication management, and post-market evidence generation are more likely to convert hospital and ASC adoption into recurring utilization. Smaller entrants may gain clearance, but clearance alone does not overcome the operational barrier created by operator dependency.

Atherectomy Devices Market Segment Analysis

Products

Orbital atherectomy accounted for 30.6% of the market in 2025 and is projected to reach USD 495.8 million by 2035 at a 6.3% CAGR. The technology uses an eccentrically mounted, diamond-coated crown that orbits at high speed to modify calcified plaque. In the ORBIT I study of heavily calcified coronary lesions, device success was 98% and procedural success was 94%. ^{[5]PubMed/National Library of Medicine, ORBIT I: Orbital atherectomy for treatment of de novo severely calcified coronary lesions. pubmed.ncbi.nlm.nih.gov} Its position is supported by the need for calcium modification before stenting, although use must remain linked to lesion morphology and not treated as a default preparation technique.

Laser atherectomy generated USD 243.3 million in 2025 and is projected to grow at a 6.5% CAGR. The segment is relevant in device-uncrossable lesions, stent underexpansion, and in-stent restenosis. A 2025 systematic review reported 96.3% procedural success and a 1.2% complication rate across 14 studies, while emphasizing its use in technically difficult coronary lesions. In femoropopliteal in-stent restenosis, laser atherectomy plus drug-coated balloon treatment improved 12-month freedom from target lesion revascularization versus drug-coated balloon treatment alone.

Directional atherectomy generated USD 199.5 million in 2025 and is forecast to expand at a 5.9% CAGR. Its selective plaque-removal capability is relevant to peripheral lesions where vessel preparation may reduce flow-limiting dissection and improve drug-coated balloon delivery. The segment's slower growth relative to rotational and laser systems reflects its dependence on specific lesion access, imaging, and operator technique.

Rotational atherectomy generated USD 158.9 million in 2025 and is anticipated to record a 6.9% CAGR. Rotational systems use high-speed diamond-coated burrs and differential cutting to modify calcified atheroma. In the PREPARE-CALC trial, a rotational-atherectomy strategy more often achieved successful lesion preparation than standard balloon predilatation before drug-eluting stent implantation in severely calcified coronary lesions. Demand is tied to calcified coronary disease, where inadequate lesion preparation can compromise stent expansion.

Application

Peripheral vascular applications represented 76.6% of the market in 2025. This share reflects the breadth of femoropopliteal and lower-extremity disease management, including calcified lesions and restenosis in patients with diabetes or chronic limb-threatening ischemia. The commercial opportunity is reinforced by the migration of peripheral procedures into ASCs and office-based laboratories, but care-site growth also heightens the need for disciplined patient selection and complication-management protocols.

Coronary applications generated USD 203.1 million in 2025 and are projected to grow at a 6.9% CAGR. Coronary use is concentrated in complex calcified lesions where balloon dilation alone may be insufficient to achieve optimal stent expansion. The segment's higher growth rate reflects the increasing importance of calcium management, but the ECLIPSE findings indicate that procedural improvements must be evaluated separately from patient-level outcome improvement.

End Use

Hospitals are expected to generate USD 1 billion through the forecast period. They remain central to complex cases because they combine catheterization infrastructure, advanced imaging, surgical backup, intensive-care resources, and multidisciplinary management. Their scale also supports structured physician training and evidence collection for newer technologies.

ASCs are projected to grow at a 6.3% CAGR. Medicare expanded reimbursement for certain percutaneous coronary interventions in ASCs in 2020, and the number of cardiology ASCs increased from 55 in 2018 to 221 in 2023. ASC technical fees are materially lower than hospital outpatient department fees, creating a cost incentive for suitable cases to shift out of hospitals. The segment will grow where patient acuity, local reimbursement, and operator capability align; it should not be interpreted as a wholesale replacement for hospital-based intervention.

Other end users include office-based laboratories and specialty vascular centers. These facilities can extend access to peripheral intervention, particularly in markets with established outpatient reimbursement, but utilization remains sensitive to physician ownership structures, local oversight, and availability of emergency transfer pathways.

End-use economics are equally decisive. Hospitals retain the most complex cases, while ASCs and office-based laboratories create a high-utilization outpatient channel for appropriately selected peripheral interventions. The winning commercial model combines device performance with procedural education, imaging compatibility, and site-of-care support that helps providers move suitable cases without extending treatment beyond their clinical capability.

Atherectomy Devices Market Regional Analysis

North America

North America held 58.8% of the market in 2025, equivalent to USD 475.6 million. The United States accounted for USD 369.1 million in 2022, USD 403.2 million in 2023, USD 438.8 million in 2024, and USD 475.6 million in 2025, with a projected 6.4% CAGR. The region benefits from established catheterization infrastructure, broad specialist availability, outpatient procedural capacity, and reimbursement pathways. U.S. PAD affects an estimated 8–10 million adults, while approximately 150,000 non-traumatic limb amputations occur annually, underscoring the clinical burden that drives revascularization demand. ^{[6]American Heart Association/Circulation, Heart disease and stroke statistics: 2023 update. ahajournals.org}

Europe

Europe generated USD 163.4 million in 2025. Market development is shaped by mature cardiovascular care systems but moderated by country-specific reimbursement, medical-device regulation, and evidence expectations. The United Kingdom illustrates the tension: NICE supports laser atherectomy with balloon angioplasty for PAD under normal governance arrangements, while plaque-excision devices for femoropopliteal lesions remain subject to special governance because of evidence-quality concerns. Germany, the UK, France, Spain, Italy, and the Netherlands remain relevant commercial markets, although atherectomy adoption cannot be inferred from regional cardiovascular demand alone.

Asia Pacific

Asia Pacific is projected to record the highest regional CAGR at 7.1%. China's PAD burden reached 41.13 million prevalent cases in 2020, with smoking, hypertension, and diabetes identified as major risk factors. ^{[7]PubMed/National Library of Medicine, Prevalence and risk factors of peripheral arterial disease in China. pubmed.ncbi.nlm.nih.gov} China's catheterization and PCI infrastructure expanded sharply during the prior decade, with PCI hospitalizations increasing from 9,678 in 2001 to 208,954 in 2011. India's growing cardiovascular burden and expanding interventional capacity similarly create a longer-term pathway for adoption. The opportunity depends on affordability, physician training, and access to advanced imaging, rather than population size alone.

Latin America

Latin America includes Brazil, Mexico, and Argentina. The region presents an emerging opportunity as cardiovascular treatment infrastructure develops, but the evidence package does not support a direct estimate of atherectomy procedure growth by country. Commercial progress will likely be uneven, concentrated in urban referral centers with endovascular expertise and procurement capacity.

Middle East & Africa

Middle East & Africa includes South Africa, Saudi Arabia, and the UAE. In the Gulf Cooperation Council, cardiovascular disease accounts for approximately 30,000 deaths annually, and diabetes prevalence ranges from 15.4% in the UAE to 18.3% in Saudi Arabia. These risk factors support long-term demand for vascular intervention, but market realization remains tied to specialist workforce availability, public funding priorities, and advanced-procedure access.

Asia Pacific provides the strongest incremental-growth profile because disease burden and interventional capacity are expanding together, especially in China and India. The region is not a uniform expansion market: suppliers must account for price sensitivity, uneven infrastructure, and the time required to develop operator confidence. Europe remains evidence-led and regulatory intensive, while Latin America and Middle East & Africa offer targeted rather than broad near-term opportunities centered on advanced referral institutions.

Atherectomy Devices Market Share & Competitive Landscape

Competition centers on clinical specialization, evidence generation, product breadth, imaging integration, physician training, and access to hospital and outpatient accounts. Abbott strengthened its orbital atherectomy position through the acquisition of Cardiovascular Systems, Inc. (CSI), adding peripheral and coronary orbital atherectomy capabilities to its vascular portfolio. ^{[8]Abbott, Expanding vascular offerings to improve patient care. abbott.com} The acquisition expanded Abbott's ability to compete in calcium-management workflows spanning diagnosis, vessel preparation, and intervention.

Medtronic's HawkOne directional atherectomy system uses a 12,000-RPM cutter and four contoured cutting blades for eccentric and concentric plaque in peripheral vessels ranging from 2.0 mm to 7.0 mm. Its peripheral-only indication underscores the importance of application-specific positioning rather than assuming cross-over demand between coronary and peripheral categories.

Boston Scientific's Jetstream system combines front-cutting expandable blades with continuous active aspiration to manage plaque, calcium, thrombus, and chronic total occlusions in peripheral vessels. In the JET Registry, procedural success was 98.3%, with 77.2% patency at 12 months in femoropopliteal lesions. ^{[9]Boston Scientific, Jetstream Atherectomy System, current. bostonscientific.com} Its aspiration-based differentiation addresses debris management, an important consideration in complex peripheral interventions.

Avinger competes through image-guided directional atherectomy. Pantheris received FDA clearance for treatment of in-stent restenosis in lower-extremity arteries and incorporates intravascular optical coherence tomography for real-time visualization during plaque removal. The company's Pantheris LV is commercially available.

AngioDynamics, Becton Dickinson and Company, Cardio Flow, MicroPort, Nipro, Philips, Ra Medical Systems, and Rex Medical remain within the competitive scope. Their competitive relevance depends on their ability to address specific procedural needs, build credible clinical evidence, and secure channel access in a market where hospitals and outpatient operators are increasingly selective about capital, disposable, and training commitments.

Recent Industry Developments

• On April 27, 2022, the U.S. Food and Drug Administration cleared the Diamondback 360 Peripheral Orbital Atherectomy System under 510(k) K220568.
• On February 8, 2023, Abbott announced its agreement to acquire Cardiovascular Systems, Inc. for approximately USD 890 million in equity value.
• On April 27, 2023, Abbott completed its acquisition of Cardiovascular Systems, Inc., making CSI a wholly owned Abbott subsidiary.
• On September 27, 2023, the U.S. Food and Drug Administration cleared the FreedomFlow Orbital Circumferential Atherectomy System under 510(k) K231538.